A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Farrant, JP, Schmitt, M, Reid, AB, Garratt, CJ, Newman, WG, Malhotra, A, Beynon, R, Mahmod, M, Raman, B, Cooper, RM, Dawson, D, Green, T, Prasad, SK, Singh, A, Dodd, S, Watkins, H, Neubauer, S and ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Another cause of sudden death is hypertrophic cardiomyopathy (HCM), a genetic condition where ... most common causes of ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

If you have cardiomyopathy, the heart muscle is dysfunctional ... You may not have any symptoms, so often, familial hypercholesterolemia is found during a routine blood test.